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Background: To investigate the efficacy of initial biopsy or transurethral resection of bladder tumor for detecting
histological variants on radical cystectomy and to assess the prognostic significance of variant histology on urothelial
carcinoma outcomes after radical cystectomy.
Methods: Clinical and histopathological characteristics of 147 patients with variant histology who underwent radical
cystectomy for urothelial carcinoma between 2006 and 2012 were assessed. Sensitivity was calculated as the
proportion of radical cystectomy specimens with a particular variant that also presented the variant in the biopsy
or transurethral resection specimen. The Kaplan-Meier method and multivariate Cox proportional hazard regression
analysis were used to estimate cancer-specific survival.
Results: Of the 147 patients, 116 (79 %) were diagnosed with a single variant histology, and 31 (21 %) had
multiple patterns. Squamous differentiation (31 %) was the most common single variant histology, followed by
glandular differentiation (28 %). Except for small cell variant (100 %), the sensitivity of biopsy and transurethral
resection was most effective for the diagnosis of squamous differentiation, 19 % vs. 40 % respectively, followed
by glandular differentiation, 11 % vs. 21 % respectively. A total of 6 % and 49 % patients could be variant-free partially
due to biopsy or complete resection(s) respectively. Presence of variant differentiation in urothelial carcinoma at
cystectomy was significantly associated with inferior survival both in univariate analysis (P = 0.005) and multivariate
analysis (HR4.48, 95 % CI:1.03-19.53).
Conclusions: Overall sensitivity of biopsy or transurethral resection to detect variant differentiation on cystectomy is
relatively low. Patients with variant differentiation on cystectomy specimens have inferior survival.
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More than 90 % of bladder cancers are urothelial carcin-
omas. Urothelial carcinoma of the bladder (UCB) has a
propensity to undergo divergent or variant differenti-
ation, resulting in a wide spectrum of subtypes [1–3].
Thirteen morphotypes were discussed in the 2004 World
Health Organization Classification of Tumours of the
Urinary Tract [4]. Since then, several new divergent sub-
types have been described [2, 5].* Correspondence: linjianbj@163.com; bdyyqhe@sina.com
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unless otherwise stated.Generally, about 7 to 81 % of bladder UCBs have some
type of variant differentiation [3, 6–8]. The recognition
of histological variants in UCB is of significance to both
pathologists and clinicians because (a) some variants
may affect prognostic consequences, (b) some may need
different modalities compared with those used in con-
ventional UCB, and (c) knowledge of the histological
variants may be crucial to avoid diagnostic misinterpre-
tations [5]. That applies, for example, to tumors consis-
ting of plasmocytoid or micropapillary components. UCB
patients with plasmocytoid histology may lead to diagnosis
delays and inappropriate therapies because of absence of
gross hematuria and the lack of visible tumor at cys-
toscopy [9, 10]. Given that micropapillary carcinoma isis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pared to traditional UCB, one leading group has suggested
early cystectomy should be taken into consideration in the
clinical management of those patients with micropapillary
histology for pTa and pT1 tumors [5, 11]. Hence, early de-
tection of variant differentiation is crucial.
However, the diagnosis of UCB variants may be chal-
lenging. A common feature of the variant patterns is
that the frequency with which they are diagnosed is
influenced by many factors: the extensiveness of the
tumor pathologically sampled, the proportion of the di-
vergent element of the whole tumor, the attentiveness
of the pathologist detecting small foci of the respective
pattern, the severity of artifact caused by tangential sec-
tioning, cautery and mechanical injury, etc. [3–5, 12].
This study was aimed at investigating the sensitivity of
biopsy and/or transurethral resection of bladder tumor
(TURBT) for detecting the histological differentiation on
radical cystectomy (RC). We also assess the prognostic
significance of variant histology in UCB at cystectomy.
Methods
Patient population and pathologic evaluation
This was a retrospective, single-institution study ap-
proved by Peking University First Hospital review board
(No. 2014692). We retrospectively reviewed all the path-
ology reports available at our institution with informed
consent for each UCB patient treated with RC from the
time of first visit to the time of RC. The variant histology
in this study are those recognized by 2004 WHO Classifi-
cation of Tumors and the literature [4, 5]. Four highly
experienced pathologists specializing in urologic patho-
logy were involved in reviewing these cases. Pathological
grade and stage were assigned according to the recom-
mendations, respectively [4, 13]. Any problematic cases
were re-reviewed by a dedicated urologic pathologist
(author QH) to verify the initial diagnoses. Any amount
of variant differentiation was reported.
Inclusion criteria: (a) From the time of first visit to the
time of RC, all the treatments were done at our hospital;
first visit was defined as patients had never received biopsy
or underwent biopsy for only once at other institutions
before coming to our hospital and the pathological
sections of biopsy were re-reviewed by the pathologists at
our medical center; (b) Detailed medical record informa-
tion was available. Exclusion criteria: (a) Patients received
TURBT(s) or partial cystectomy at other institutions
before initiation of therapy at our institution; (b) Patients
presented extravesical malignant primary tumors before
RC; (c) Patients underwent biopsy or TURBT without
subsequent RC as well as any with pure nonurothelial
morphology [1].
Between 2006 and 2012, a total of 620 consecutive pa-
tients were treated with RC for UCB at Peking UniversityFirst Hospital. Ultimately, 147 patients who met all the
above-described criteria with a diagnosis of variant diffe-
rentiation in pure or mixed form after RC, the matched
preceding biopsy or TURBT(s), were included in this study.
Among those patients, 63 who underwent biopsy only once
without TURBT were included in the analysis of biopsy
sensitivity, while the remaining 84 who underwent TURBT
at least once were used to calculate the sensitivity of
TURBT. For study purposes TURBT was defined as resec-
tion of all visible tumor while biopsy partial sampling [1].
Follow-up
Follow-up was performed generally quarterly for the first
year, semiannually for the next 2 years and annually
thereafter with laboratory and imaging studies unless
otherwise clinically indicated. Outcomes of interest was
cancer-specific survival (CSS). CSS duration was calculated
from date of cystectomy to death due to bladder cancer;
surviving patients were censored at last follow-up [14, 15].
Statistical analysis
Sensitivity was calculated as the proportion of RC speci-
mens with a particular variant that also had the variant
in the biopsy or last TURBT (LTURBT) specimen [1].
The Kaplan–Meier method was used to graphically dis-
play survivor functions. Multivariate Cox proportional
hazards models were used to estimate independent rela-
tionships between categorical variables that were univari-
ably prognostic for CSS. The assumptions of proportional
hazards with respect to the log-hazard were checked using
the Schoenfeld residual test and no major model viola-
tions were observed. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC, USA) and/or
SPSS version 20.0 (IBM Corp, Armonk, NY, USA). Two-
sided P ≤ 0.050 was considered statistically significant.
Results
Histologic spectrum of variant differentiation
Of the 147 patients, 116 (79 %) were diagnosed with a
single variant histology, whereas the remaining 31 (21 %)
had multiple patterns of variant histologic components on
RC, the matched preceding biopsy or TURBT(s). In de-
creasing order of frequency, the spectrum of divergent dif-
ferentiation included: squamous (31 %), glandular (28 %),
sarcomatoid (12 %), small cell (2 %), clear cell (2 %),
microcystic (2 %), lymphoepithelioma-like (1 %), and un-
differentiated (1 %).
Sensitivity of biopsy or TURBT for detecting histological
variants on RC
The sensitivity of biopsy and LTURBT to detect a cer-
tain variant varied (Table 1). Except for small cell variant
(100 %), the sensitivity of biopsy and LTURBT was most
effective for the diagnosis of squamous differentiation,
Table 1 The sensitivity of biopsy and LTURBT for detecting variant differentiation
Variant No. biopsy RC % sensitivity No. LTURBTa RC % sensitivity
Squamous 8 28 19 26 20 40
Glandular 4 27 11 18 19 21
Sarcomatoid 0 19 0 14 11 9
Small cell 1 1 100 1 3 0
Lymphoepithelioma-like 0 3 0 0 0 0
Plasmacytoid 0 1 0 0 1 0
Clear cell 0 2 0 0 3 0
Nested 0 0 0 1 0 0
Microcystic 0 3 0 1 1 0
Undifferentiated 0 1 0 0 0 0
aLast transurethral resection of bladder tumor precystectomy
Table 2 Variants detected on TURBT and RC of patients who
underwent TURBT at least twice (n = 13)
Patient ID No. TURBTa No. variantb RCc Variant (TURBT/
No.TURBT)d
1 6 1 Glandular Sarcomatoid (6/6)
2 5 1 UCe Clear cell (1/5)
3 4 1 Glandular Glandular (4/4)
4 4 2 UC Squamous (2/4),
Nested (4/4)
5 3 1 Sarcomatoid Glandular (3/3)
6 2 1 Glandular Squamous (2/2)
7 2 1 Squamous Squamous (2/2)
8 2 2 Squamous Squamous (1/2),
Squamous (2/2)
9 2 1 UC Squamous (1/2)
10 2 1 UC Small cell (2/2)
11 2 1 UC Squamous (1/2)
12 2 1 UC Sarcomatoid (1/2)
13 2 1 UC Squamous (1/2)
All the specimens were re-reviewed by a dedicated pathologist QH
aThe total number of TURBT
bThe total number of TURBT with a diagnosis of variant differentiation
cThe diagnosis of radical cystectomy specimen
dTURBT/No.TURBT = The ordinal number of TURBT with a diagnosis of variant
differentiation / The total number of TURBT
eUrothelial carcinoma without variant differentiation
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tiation, 11 % vs. 21 % respectively. Sarcomatoid variant
with a sensitivity of 9 % was only detected on LTURBT.
Surprisingly, it seemed to be invalid for biopsy or
LTURBT to detect lymphoepithelioma-like (0 %), plasma-
cytoid (0 %), clear cell (0 %), nested (0 %), and undifferen-
tiated variant (0 %).
Forty-five patients (31 %) exhibited variant(s) only on
biopsy or TURBT(s), including 4 cases for biopsy, and
41 cases for TURBT(s). In other words, this suggested
that the efficacy of biopsy and TURBT(s) upon removing
the variant components during the disease course was
6 % (4 of 64) and 49 % (41 of 84) respectively partially
due to extensive sampling and complete resection. There
were 71 patients who underwent TURBT only once and
13 underwent TURBT at least twice (varying from twice
to six times) during the time of first visit to the time of RC.
For those who underwent TURBT only once, 34 (48 %)
were found free of variant complements on RC. Inter-
estingly, for patients who underwent TURBT at least
twice, 5 patients were diagnosed with different variant
histologic subtypes on RC, the matched preceding bio-
psy or TURBT (Table 2).
Cancer-specific survival
Follow-up information was available for 139 patients
(94.6 %); 28 patients died of bladder cancer during follow-
up. The mean age of the 139 patients was 66 years
(SD:11.1). The median follow-up was 31 months (range 2–
90). Of those, 95 UCB patients were identified with va-
riant differentiation on RC specimens. Fig. 1 shows that
variant differentiation on RC was statistically signifi-
cantly associated with inferior survival (P = 0.005). Simi-
larly, multivariate analyses after being adjusted for the
effects of pathologic stage demonstrated that presence of
variant differentiation in urothelial carcinoma at cystec-
tomy was independently associated with cancer-specific
mortality (HR4.48, 95 % CI:1.03-19.53).Discussion
In this current study, we investigated the sensitivity of
biopsy and/or TURBT for detecting the histological
differentiation on RC and assessed the prognostic sig-
nificance of variant histology on urothelial carcinoma
outcomes after RC. Our results indicate that overall sen-
sitivity of biopsy or TURBT to detect variant diffe-
rentiation on RC is relatively low. Presence of variant
differentiation in urothelial carcinoma at cystectomy
portends inferior survival.
Fig. 1 Kaplan-Meier plot displays estimated cancer-specific survival in 139 patients treated with radical cystectomy, stratified by pure vs. variant
differentiation in urothelial carcinoma at cystectomy (UC, urothelial carcinoma)
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great propensity to undergo variant differentiation. In
accordance with previous studies [3, 15], the most preva-
lent mixed differentiation in this current series was
squamous, accounting for 31 % of all cases. Squamous
differentiation, characterized by the presence of intercel-
lular bridges, keratin pearls or keratinization, has an
unfavorable response to radiation and chemotherapy
compared with pure UCB [5]. Previous studies have
shown that its frequency runs parallel with grade and
stage [16, 17]. Glandular differentiation, as the second
common variant, is exemplified by the presence of true
glandular spaces within the tumor, presented in 28 % of
all cases [4]. After squamous and glandular subtypes,
there is sarcomatoid differentiation, which is featured
by biphasic malignant neoplasms with the evidence of
expressing epithelial and mesenchymal markers, account-
ing for 12 % of all cases. In a sarcomatoid carcinoma, mo-
lecular evidence strongly argues for a monoclonal origin
of both epithelial and mesenchymal components [18, 19].
Additionally, history of previous radiation or cyclophos-
phamide can be a valuable clue in ascertaining the diag-
nosis [4]. Other unusual architectural patterns (small
cell, lymphoepithelioma-like, clear cell, microcystic,undifferentiated) of UCB only accounted for a little
proportion of the whole, namely 8 %. Those variants,
compared with squamous and glandular differentiation,
are more complicated for the pathologist to reach a direct
diagnosis and can sometimes mimic reactive processes,
benign lesions or metastasis of other tumors. For instance,
lymphoepithelioma-like carcinoma, for which the sine que
non feature is the presence of a pronounced lymphoid
infiltrate, may be partially or substantially obscured by
a variable desmoplastic response, a brisk inflammatory
infiltrate and even a prominent chronic inflammatory
cell infiltrate [5].
Although some studies have contributed to raising the
awareness of these entities and improved diagnosis,
the diagnosis of UCB variants may still be challenging
for (a) the limitation of biopsy samples and transurethral
resectates available to the pathologist, (b) the artifact
caused by tangential sectioning, cautery and mechanical
injury, and (c) even more importantly the difficulty of
discriminating over selected mimics [3–5, 12]. In this
study, the most sensitive variants detected by biopsy and
LTURBT are squamous and glandular subtypes. This fin-
ding corroborates a previous study in which Ahmed et al.
reported that the sensitivity of TURBT to detect squamous
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Similar to the squamous differentiation, the sensitivity of
LTURBT to detect glandular variant is nearly twice as that
of biopsy. Compared to other variants, the sensitivity of
biopsy and LTURBT to detect squamous and glandular
differentiation was relatively higher. For most variants,
Table 1 suggests an unfavorable sensitivity. However, con-
sidering their nature of rarity, more studies based on multi-
center and/or international collaboration with large sample
size are warranted to further validate these conclusions.
It is well known that sensitivity lies in correct diagno-
ses. In order to make a correct diagnosis, several points
should be noted. First, recognition of the immunochemical
profile is quite important for pathologists to distinguish
certain variants from the confounding variables. Mahul
et al. [5] summarized the immunohistochemical markers
associated with urothelial differentiation in detail. Second,
morphology should be made the best advantage. One case
in point is that immunohistochemistry is less significant
compared with morphology in discrimination nested
variant over florid von Brunn’s nests, as the reliable im-
munohistochemical cut-point is difficult to be deter-
mined [12]. Besides, in some cases, clinicopathological
correlation is helpful in excluding an extravesical primary
tumor [5]. Recently, Hughes et al. [20] have reported the
effect of Fourier transform infrared (FTIR) microspectro-
scopy to diagnose some selected variants, which might
open a new door for variant diagnosis.
In this study, we found that 49 % patients who under-
went TURBT at least once were not diagnosed with vari-
ants on RC specimens. That is to say, approximately 50 %
of the patients could be in variant-free condition partially
due to complete resection(s). Dissimilarly, Ahmed et al.
reported that 6 % (9/159) patients demonstrated variant(s)
only on precystectomy biopsy or TURBT [1]. The factors
that could influence the variant diagnosis could also ex-
plain the discrepant results between the two studies. Inter-
estingly, among the 13 patients who underwent TURBT at
least twice, 12 of them presented variants detected in
some but not in all TURBTs (Table 2). Similarly, Matthew
et al. found that some patients had a different or addi-
tional mixed histologic type on cystectomy than they did
on transurethral resection of bladder tumor [21]. This
raises several practical questions encountered in clinical
work. First, for those who are diagnosed with different
variant differentiation at biopsy, TURBT(s) or RC, what
treatment algorithms should be applied in clinical man-
agement? Besides, for those who are diagnosed with
variant differentiation at biopsy/TURBT and without
variant subtype diagnosis on RC, should we adopt the
same follow-up strategies used on the UCB patients
without a diagnosis of variant differentiation during the
disease course? Further investigations are needed to
validate the paradigms.Despite a number of individual studies have evaluated
the impact of histological variants on prognosis of patients
with UCB, this question remains in debate [14, 22]. We
also evaluated the impact of variant differentiation on
clinical outcomes. Of the 139 patients with available
follow-up information, 95 UCB patients were identified
with variant differentiation on RC specimens. Patients
with variant differentiation on RC specimen have inferior
survival both in univariate analysis (P = 0.005) and multi-
variate analysis (HR4.48, 95 % CI:1.03–19.53). Of note,
our data were limited by an overall shorter median follow-
up time of 31 months and small sample size. The sta-
tistical power was weakened by very few recurrent and
death events. More investigations with a large number
of patients, with a longer follow-up time and with a cen-
tralized pathologic re-review are warranted to validate
these conclusions. Ultimately, our understanding of
urinary bladder cancer biology should not be limited to
histologic variants. The underlying genetic and molecu-
lar drivers of tumor induction, promotion, and progres-
sion and as well as makers of chemosensitivity also need
to be investigated [14].
Our study is not devoid of potential limitations that need
to be addressed. First and foremost are the limitations in-
herent to its retrospective nature. Besides, the follow-up
time and sample size were the limitations of this study.
Conclusions
Overall sensitivity of biopsy or TURBT to detect variant
differentiation on RC was relatively low. Nearly 50 % of
the patients could be variant free partially due to
complete resection(s). Patients with variant differenti-
ation on RC specimen have inferior survival. Further
studies on the approach to early detection of variant dif-
ferentiation and the management tactics for the UCB pa-
tient presenting different variant differentiation at biopsy,
TURBT or RC, may be facilitated.
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